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Abstract
Background: Chronic Non-Bacterial Osteomyelitis (CNO) is an inflammatory disorder that primarily affects children.
Although underestimated, its incidence is rare. For these reasons, no diagnostic and no therapeutic guidelines exist.
The manuscript wants to give some suggestions on how to deal with these patients in the every-day
clinical practice.
Main body: CNO is characterized by insidious onset of bone pain with local swelling. Systemic symptoms
such as fever, skin involvement and arthritis may be sometimes present. Radiological findings are suggestive for
osteomyelitis, in particular if multiple sites are involved. CNO predominantly affects metaphyses of long bones, but
clavicle and mandible, even if rare localizations of the disease, are very consistent with CNO diagnosis. CNO
pathogenesis is still unknown, but recent findings highlighted the crucial role of cytokines such as IL-1β and IL-10 in
disease pathogenesis. Moreover, the presence of non-bacterial osteomyelitis among autoinflammatory syndromes
suggests that CNO could be considered an autoinflammatory disease itself. Differential diagnosis includes infections,
malignancies, benign bone tumors, metabolic disorders and other autoinflammatory disorders. Radiologic findings, either
with Magnetic Resonance or with Computer Scan, may be very suggestive. For this reason in patients in good clinical
conditions, with multifocal localization and very consistent radiological findings bone biopsy could be avoided. Non-
Steroidal Anti-Inflammatory Drugs are the first-choice treatment. Corticosteroids, methotrexate, bisphosphonates, TNFα-
inhibitors and IL-1 blockers have also been used with some benefit; but the choice of the second line treatment
depends on bone lesions localizations, presence of systemic features and patients’ clinical conditions.
Conclusion: CNO may be difficult to identify and no consensus exist on diagnosis and treatment. Multifocal
bone lesions with characteristic radiological findings are very suggestive of CNO. No data exist on best treatment option
after Non-Steroidal Anti-Inflammatory Drugs failure.
Keywords: Chronic Non-Bacterial Osteomyelitis, Chronic recurrent multifocal Osteomyelitis, Autoinflammatory syndrome,
Magnetic resonance, Treatment, Bisphosphonate, Anti-TNFα treatment
Background
Chronic Non-Bacterial Osteomyelitis (CNO) is a rare in-
flammatory disorder not related to infectious disease [1]. It
was first described in 1972 by Giedion et al. [2] as a sym-
metric multifocal bone lesions; later, in 1980, Bjorksten B et
al. [3] first used the term CNO in order to identify a clinical
condition which is characterized by recurring episodes or
persisting presence of chronic sterile osteomyelitis [4–6].
Multiple names have been used in literature to describe this
disorder; these include chronic recurrent multifocal osteo-
myelitis (CRMO) in cases with extended multifocal involve-
ment (often symmetric) and synovitis, acne, pustulosis,
hyperostosis, and osteitis syndrome (SAPHO), which usu-
ally manifests in adolescent and adult patients and which
distinguishes for skin involvement [7]. The terms CRMO
and CNO are often used interchangeably. Although CNO
is still considered a rare disorder, its incidence is probably
underestimated. In fact, in a single center retrospective
study, it has been recently demonstrated that the incidence
of CNO is similar to infectious osteomyelitis [8]. For these
reasons, in absence of standardized diagnostic work out
and treatment guidelines, it is important to provide some
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clinical practical suggestion about the every-day clinical
management of CNO patients.
Main Text
Pathogenesis
Since this is not the main aim of the manuscript, CNO
pathogenesis will be only briefly discussed. Although
CNO pathogenesis is still not clear, the hypothesis that
the disorder could be sustained by infections was not
confirmed by extensive microbiological analyses and
uselessness of antibiotic treatment [4]. Findings indicate
that pro-inflammatory cytokines such as IL-6 and TNF-a
as well as anti-inflammatory (IL-10) [4, 9], IL-1β [10]
and IL-10 [11] may play an important role in disease
pathogenesis of CNO. In the last years, the hypothesis
that CNO might be a genetic disease in the spectrum of
autoinflammatory disorders has acquired even more im-
portance. The strongest evidence comes from the so
called syndromic forms of CNO: Majeed syndrome [12,
13], Cherubism [14], Hypophosphatasia [15] and Primary
Hypertrophic Osteoarthropathy [16]. In addition, chronic
osteomyelitis is a typical feature of two monogenic
diseases caused by mutations of genes involved in the acti-
vation of the NLRP3 inflammasome or in the homeostasis
of IL-1, namely pyogenic arthritis, pyoderma gangreno-
sum and acne (PAPA) syndrome [17] and the deficiency of
IL-1 receptor antagonist (DIRA), [18] respectively. There
is also some evidence for a genetic basis in non-syndromic
or sporadic CNO [19]. Moreover, in largest cohorts of
CNO patients, the prevalence of the disease among
patients’ relatives was higher [20] and some reports have
described families with multiple affected members [21] or
have reported a high incidence of psoriasis, inflammatory
bowel disease, and other chronic inflammatory conditions
in first-degree family members of individuals with CNO
suggesting that there is a significant genetic component to
disease susceptibility [3, 6]. In mice, homozygous muta-
tion of PSTIPI2 gene results in an autoinflammatory
disease very similar to CNO [22, 23].
Clinical features
The clinical manifestations of CNO are highly variable.
CNO typically presents with bone pain that is worse at
night and occurs in the presence or absence of fever [20,
24]. The onset is typically insidious, and most children
appear well.
Swelling and heat of the involved bone are not necessar-
ily always present. In 30% of cases CNO involves the adja-
cent joint with the presence of exudate, synovial
thickening and/or damage to the articular cartilage. The
lesions may affect any bone segment. One to 20 sites can
be affected at one time. The main sites of involvement in
order of decreasing frequency are the lower extremities,
pelvis, clavicle and spine [6, 20, 24]. Metaphyseal area is
the most common bone site localization as well as the in-
volvement of clavicle, mandible and sternum which is par-
ticularly suggestive of CNO [20]. The skull involvement
has been described in the occipital bone in only one case.
In this patient, however, the lesion was not present at time
of diagnosis, but it developed after 1 year from diagnosis
[25]. Skull involvement should always be considered a po-
tential malignancy; in this case bone biopsy is mandatory.
Systemic symptoms are subtle and may be present in
the form of low-grade fever, malaise, or poor growth. In
this case, malignancies, most of all acute lymphoblastic
leukemia, and inflammatory bowel disease must be
ruled out. Current estimates suggest that approximately
25% of individuals with CNO have manifestations in-
volving organ/systems other than bone [20]. The extra
- articular manifestations include the skin (especially
Psoriasis, Palmoplantar Pustulosis, Acne, Pyoderma
Gangrenosum and Sweet Syndrome) and the bowel
(Crohn Disease, Ulcerative Colitis, Celiac Disease) [26].
Renal involvement has been demonstrated in almost
10% of patients [27].
The disease may follow a chronic or recurrent disease
course, often the course is prolonged over several years
with periodic exacerbations [1–6]. The prognosis is gener-
ally good and provides self-resolution in a time ranging
from months to years. However, recently complications of
entity variable from mild to incapacitating have been
described in a considerable percentage of cases (30 to
50%). In particular asymmetries of limb length, kyphosis,
chronic spondylo-arthropathy, vertebral collapse and
stunting for early closure of the growth-cartilages have
been reported [6, 7, 24]. Monophasic disease is usually less
severe and prognosis is excellent being, in most cases, al-
most a cosmetic problem.
Diagnosis
CNO is a diagnosis of exclusion. Differential diagno-
ses include infections (septic osteomyelitis, typical and
atypical mycobacterial infections, etc.), malignancies
(primary bone tumors and leukemia/lymphoma), be-
nign bone tumors (osteoid osteoma), trauma, meta-
bolic disorders (including hypophosphatasia), other
autoinflammatory disorders (DIRA, PAPA, Cherubism,
etc.), osteonecrosis and osteopetrosis.
The most common clinical challenge is with acute bac-
terial osteomyelitis; in this case, however, pain and fever
are usually present and, except for some rare circum-
stances, such as severe immunodeficiencies, the disease
is always monofocal. In early stage of the disease, and in
the monofocal course, the radiological assays may be un-
distinguishable and a trial with antibiotics is indicated. If
there will be no response to antibiotic treatment, once
ruled out infective complication (e.g. bone abscess),
CNO should be taken into account. Malignancies should
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be considered in any patients with poor clinical condi-
tions, with systemic features, with skull involvement or
with suggestive radiologic lesions. Osteoma Osteoid has
a very typical radiological pattern (nidus surrounded by
dense bone) and nocturnal pain is almost even present.
Hypophosphatasia is an inherited disorder that affects
the development of bones and teeth. This condition dis-
rupts bone mineralization, causing skeletal abnormalities
similar to rickets. However, the forms of hypophosphata-
sia that appear in childhood or adulthood are typically
less severe than those that appear in infancy and may
present as genu varum or genu valgum, enlarged wrist
and ankle joints, and an abnormal skull shape leading to
CNO diagnosis. CNO may be present in other autoinflam-
matory disorders; however, in this case, many other clin-
ical features may prevail such as arthritis, pustulosis,
hepatomegaly, interstitial pneumonia, splenomegaly, fever
and etc. Differential diagnosis are summarized in Table 1.
Laboratory investigations may reveal mild elevation in
white blood cell count and in inflammatory parameters
(C-Reactive Protein; Erythrocyte Sedimentation Rate),
but often these abnormalities are absent in CNO pa-
tients [20, 24]. Cultures of blood and bone are invariably
negative, and sophisticated assays to identify evidence of
a microbial etiology have been unsuccessful. Autoanti-
bodies (antinuclear antibodies, rheumatoid- factor), as
well as carriage of the HLAB27 allele, have the same
prevalence in CNO patients when compared to healthy
individuals. At present, no specific biomarkers are avail-
able for the diagnosis or prediction of flares in CNO pa-
tients. In 2007 Jansson et al. [24] proposed diagnostic
criteria for CNO according to which diagnosis could be
formulated if present 2 majors and one minor criteria or
one major and three minors criteria. However, these cri-
teria are not still internationally validated and accepted
so far. A crucial role in the diagnosis of this condition is
provided by imaging and biopsy.
The role of radiology
Standard radiography of bones could not reveal char-
acteristic changes in early CNO, while the presence
of osteolytic lesions with a sclerotic edge in X-ray
imaging is the key feature later. Clavicular lesions and
mandibular often have a more prominent sclerotic
appearance [28].
Cortical bone is usually unaffected and thickened but
there are also reports of cortical defect mimicking
tumor. The involvement of the mandible is often associ-
ated with mandibular nerve canal enlargement (Fig. 1).
CNO is a systemic disorder that can affect multiple skel-
etal sites. Isotopic bone scan and/or whole-body
Magnetic Resonance (MR) are the cornerstone for con-
firming the multifocal pattern of CNO, even if bone scan
may be falsely negative in some cases. However, if iso-
topic bone scan may just confirm the presence of one or
more foci of inflammation, MR may also add more in-
formation concerning the types of lesions being the
more sensitive and accurate radiological examination at
CNO diagnosis.
The typical MR findings are the presence of bone cor-
tical thickening, lytic lesions with sclerosis and bone
edema. Moreover, MR is particularly important in the
early stages of the disease for its ability to detect bone
edema and also asymptomatic bone lesions [29], before
osteolysis and/or sclerosis can be detected. On the other
hand, it should be mentioned that, due to its high
sensitivity, this technique might lead to an over-
interpretation of some bone lesions that, especially in
pediatric age, can be related to normal bode growth or
accidental traumatic events. This issue should be taken
into careful consideration if the site of the bone biopsy
is chosen on the basis of the MR images. Due to the lack
of ionizing radiation, total body MR (with STIR se-
quences) is currently used to monitor the evolution of
the bone lesions during the follow-up. Again, due to its
Table 1 Clinical characteristics of CNO compared with other bone diseases
CNO Bacterial Osteomyelitis Malignancy Osteoid Osteoma DIRA PAPA Cherubism Osteopetrosis
Multifocal Involvement +++ – + – + −/+ + +++
Pain ++++ ++++ ++++ ++++ ++ +++ ++ ++
Fever + +++ −/+ – −/+ −/+ – –
Skin Involvement + – – – ++++ +++ – –
Articular Involvement + ++ – – ++++ ++++ – –
Bone Swelling +++ −/+ ++ – ++ ++ ++++ ++
Renal Involvement + – −/+ – – + – –
Hepatosplenomegaly – – + – ++++ – – ++
Early Age of onset −/+ + −/+ – ++++ – – ++
ESR/CRP elevation + +++ −/+ – ++++ ++++ – –
Leukocytosis −/+ +++ −/+ – ++++ ++++ – –
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high sensitivity MR might provide signs of possible bone
activity in a subgroup of patients which did not com-
plain any clinical manifestation or bone pain and could
be considered in clinical remission [30]. For this reason
it is not clear if the evidence of radiological disease activ-
ity in spite of a persistent clinical and laboratoristic, re-
mission should be taken into consideration for patient’s
treatment strategy or, vice versa, if it could lead to an
over-treatment in some patients. For this reason, longi-
tudinal MR control could be useful in particular among
patients with a more severe disease course and resistant
to ongoing treatments, and in case of the involvement of
some specific sites, such as the mandible or the spine,
which is traditionally characterized by a higher rate of
complication such as scoliosis or kyphosis.
The role of biopsy
Although no formal guidelines are so far available, a bi-
opsy of the bone lesion is usually performed, mainly to
exclude other causes. In CNO bone biopsy shows signs
of inflammation in the absence of infection. The com-
position of cellular infiltrates at the sites of inflammation
is strictly correlated to the “age” of biopsied lesions.
Neutrophils are predominant in early lesions, whereas
lymphocytes, macrophages and plasma cells can be de-
tected during the later course of the inflammatory. The
final stage of the lesion is characterized by the predom-
inance of fibrosis. The cultures of the biopsy are always
negative [4].
Although histological findings are specific, the main
role of the biopsy is to rule out malignancy such as his-
tiocytosis, Ewing sarcoma, osteosarcoma, leukemia and
lymphoma. All these disorders should be considered in
the differential diagnosis of persistent bone pain in all
age groups.
Recently, Jansson et al. proposed a clinical score that
could facilitate the diagnosis and treatment process, es-
pecially with respect to the decision on whether to carry
out invasive procedures required for diagnosis of these
diseases [31]. Even if the Jansson Score is not still widely
validated, it is suggested that patients with a score > 39
could not undergo biopsy. Our practical approach is to
perform a biopsy in all patients with poor general condi-
tions, persistent and significant elevation of acute phase
reactants and/or hematological abnormalities (anemia,
alteration in leukocyte or platelet counts), and all those
patients with unifocal or atypical (i.e. skull) bone in-
volvement. In these cases, the biopsy may be performed
in the most accessible lesion. On the contrary, the deci-
sion to perform the biopsy can be postponed in those
patients with good general conditions, with slight eleva-
tion of acute phase reactants, involvement of multiple
and/or typical and bone sites, typical radiological find-
ings and favorable response to Non-Steroidal Anti-
Inflammatory Drugs (NSAIDs) treatment (Fig. 2). In any
case, further studies are needed to clarify the role of bi-
opsy; to now the decision to perform the biopsy remains
a physician related decision based on his expertness and
knowledge toward CNO diagnosis.
Treatment
Generally accepted treatment protocols for CNO do not
exist and the treatment of CNO has been largely em-
piric. A number of retrospective assessments of response
to treatment in case reports or small series are available
in the literature. Neither Guidelines nor expert consen-
sus treatment do exist for CNO so far; however our
group has recently proposed a suggested treatment
protocol base exclusively on their clinical expertise [32].
The first line treatment is usually NSAIDs, which have
been demonstrated useful for pain control and inducing
remission in a percentage of patients varying from 43 to
83% [24, 33]. The NSAIDs more frequently used are na-
proxen, indomethacin and, especially, in those patients
with concomitant inflammatory bowel disease, sulfasala-
zine. The prospective use of NSAIDs has been evaluated
in a single study performed in thirty-seven CNO pa-
tients. A favourable clinical course identified as
Fig. 1 MR of mandible. Mandible edema and mandibular nerve canal
enlargement (arrow) in a CNO patient
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symptoms free status was reported in 43% of patients
taking naproxen at 1 year of follow-up; moreover, the
total number of clinical detectable lesions was signifi-
cantly reduced. Mean disease activity estimated by the
patient/physician and the physical aspect of health-
related quality of life including functional ability (global
assessment/childhood health assessment questionnaire
and childhood health assessment questionnaire) and
pain improved significantly [33]. At least 1 month trial is
needed in order to determine their failure. However, it is
important to underline that NSAIDs did not seem to be
sufficient for vertebral involvement or in case of periph-
eral arthritis. In case of NSAIDs failure, a single course
of corticosteroids could be beneficial at the beginning of
the disease; some others suggest their use only in those
cases unresponsiveness to NSAIDs, in relapsing diseases
or in severe clinical involvement [33, 34]. In this case, a
bone biopsy should precede the use of steroid; prednis-
olone is usually the drug of choice.
TNF-alfa inhibitors have also been used in CNO pa-
tients. Infliximab was the first biologic treatment used
[35] in an 18-years old with relapsing CNO. Etanercept
has also been demonstrated effective in a patient with
active disease despite previous treatment options, to-
gether with Methotrexate (MTX) [36]. Some large co-
horts of patients report their use in a small sample of
patients, usually <10%, who did not achieve clinical
remission with previous treatment. In these patients,
their use was usually of benefit [20, 24].
In the last years, the use of bisphosphonate was found
to be effective and safe in the treatment of CNO. Most
part of data about bisphosphonate use is based on case
reports or small case series [37]. The most common used
molecule is pamidronate, but alendronate has been re-
ported to be safe and useful as well [38]. Bisphosphonates
have demonstrated to be effective not only in controlling
pain, [39] but recently it has also been demonstrated their
efficacy in the resolution of bone lesions assessed by
whole body magnetic resonance imaging [40]. At the mo-
ment it is not clear whether treatment option is better.
Wipff et al. suggested that CNO patients may be divided
into three categories of clinical severity. The patients with
a mild phenotype presented a high remission rate irre-
spectively from treatment and use of pamidronate or TNF
inhibitors; on the contrary, among the severe phenotype,
the rate of clinical remission was lower despite high
percentage of patients undergoing treatment with bipho-
sphonate or TNF inhibitors [20]. In our experience bis-
phosphonate were the most useful treatment option
irrespectively of previous treatment or clinical features
[27]; in fact we have demonstrated that bisphosphonates
may lead to remission the 73% of CNO patients after
NSAIDs and steroids failure. For this reason, we would
suggest that bisphosphonate could be considered the
first treatment options for CNO patients when
NSAIDs failed, especially when the spine is involved.
Their safety is debated. Although to date, jaw osteo-
necrosis has never been reported in pediatric patients
with CNO, periodic oral controls are recommended.
In patients with concomitant gastro-intestinal or ar-
ticular involvement (synovitis, spondylitis), sulfasala-
zine, MTX or anti-TNF treatment can be considered
as treatments of choice. Data reporting clinical studies
on CNO treatment are summarized in Table 2.
Fig. 2 Suggested diagram to perform or not perform bone biopsy in a patient with suspected CRMO
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All monogenic forms of CNO (DIRA, Majeed syndrome
and PAPA) respond really well to anti-IL1 blockade, [41–
43] and, even if its role it is not clear in CNO, it has been
recently demonstrated that Anakinra may be a possible
therapeutic alternative in patients with refractory CNO [44].
The lack of longitudinal, placebo-control large studies
on the different possible therapeutic strategies unable us
to indicate an evidence-based approach to the treatment
of this enigmatic and protean condition. Thus, the optimal
treatment strategy for CNO remains to be determined.
Conclusions
CNO is a rare disorder and many considerations about
diagnosis and treatment remain to be clarified. However,
clinical features, the presence of multifocal lesions and
radiologic features may help in diagnosis avoiding bone
biopsy. NSAIDs remain the first treatment option, while
bisphosphonates and TNF-alpha inhibitors could be
considered the best second line treatment option. Even
if CNO is often a benign disease, it can lead to severe
and persistent complications.
Abbreviations
CNO: Chronic non-bacterial osteomyelitis; CRMO: Chronic recurrent
multifocal osteomyelitis; DIRA: Deficiency of IL-1 receptor antagonist;
MR: Magnetic resonance; NSAIDS: Non-steroidal anti-inflammatory
drugs; PAPA: Pyogenic arthritis, Pyoderma gangrenosum and acne
syndrome; SAPHO: Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis
syndrome
Table 2 List of manuscripts reporting data about response to treatment of patients with CNO
Reference Nr. patients Treatment Response to treatment
Wipff J et al., 2015 [20] 178 NSAIDs 126/178 (71%): clinical response
Sulfasalazine 7/17 (41%): clinical response
Methotrexate 3/8 (37%): clinical response
Bisphosphonates 6/8 (75%): clinical response
Anti-TNFα 8/9 (89%): clinical response
Jansson A et al., 2007 [24] 89 NSAIDs 64/77 (83%): clinical response
Steroids 13/13 (100%): transient response
DMARDs 6/6 (100%): no response
PAM 1/4 (25%): clinical response
1/4 (25%:) partial response
2/4 (50%): no response
Kaiser D et al., 2015 [45] 41 NSAIDs 21/37 (57%): clinical response
Methotrexate 6/7 (86%): no response
Bisphosphonates 1/5 (20%): clinical response
1/5 (20%): partial response
Etanercept 2/8 (25%): clinical response
Beck C et al., 2010 [33] 37 Naproxene 16/37 (43%) clinical response
Indomethacin 4/7 (57%) clinical response
Diclofenac 9/12 (75%) clinical response
Others NSAIDs 6/19 (32%) clinical response
Sulfasalazine 4/5 (80%) clinical response
Steroids 4/4 (100%) clinical response but recurrence during dosage tapering
Roderick M et al., 2014 [40] 11 PAM 8/11 (73%) clinical response
Miettunen PM et al., 2009 [46] 9 PAM 9/9 (100%) clinical and radiological response
Gleeson H et al., 2008 [39] 7 PAM 6/7 (86%) clinical response
Hospach T et al., 2010 [47] 7 PAM 7/7 (100%) clinical response and radiological improvement
Kerrison C et al., 2004 [48] 7a PAM 7/7 (100%) clinical remission
Batu ED, et al., 2015 [49] 5 Etanercept 5/5 (100%) clinical response
Simm PJ et al., 2008 [37] 5 PAM 4/5 (80%) clinical response and radiological improvement
Eleftheriou D et al., 2010 [50] 4 anti-TNFα 2/3 clinical response to infliximab, 1/3 response to adalimumab
DMARDS Disease-modifying anti-rheumatic drugs (Methotrexate or Azathioprine), NSAIDs Non-steroidal anti-inflammatory drugs, PAM Pamidonate
apatients with SAPHO
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